Bispecific Nanobody Broadly Neutralizes and Cross-Protects against Three Highly Pathogenic Human Coronaviruses

Abstract SARS-CoV, SARS-CoV-2, and MERS-CoV continue to infect humans or pose a threat of future outbreaks, highlighting the ongoing need for effective, broad-spectrum therapeutics that target these highly pathogenic coronaviruses. As single-domain antibodies, nanobodies have a small size, high target-binding affinity, exceptional stability, low production costs, and the ability to access otherwise hidden or cryptic epitopes. Here, we identified nanobodies targeting SARS-CoV, SARS-CoV-2, and MERS-CoV receptor-binding domains (RBDs) using phage display libraries derived from immunized nanomice and generated a bispecific nanobody to evaluate its broadly neutralizing activity and cross-protective efficacy. Nanobodies 2F11 and 4D6 targeted SARS-CoV RBD, potently neutralizing the SARS-CoV original (Tor2) strain, whereas nanobody 3B11 targeted both SARS-CoV and SARS-CoV-2 RBDs, broadly neutralizing all three SARS-CoV strains (Tor2, GD03, and SZ3) and divergent SARS-CoV-2 variants. Among MERS-CoV RBD-targeting nanobodies, 1C11 demonstrated broadly neutralizing activity against multiple MERS-CoV strains, while its Fc-fused version substantially enhanced the neutralizing potency. These nanobodies exerted neutralizing effects by blocking the interaction between the RBDs and their respective receptors. Cryo-EM structures, computational modeling, and epitope-mapping analyses revealed unique epitopes of 2F11, 3B11, and 1C11 on the SARS-CoV, SARS-CoV-2, or MERS-CoV RBD, underlying their antiviral potency. Finally, a bispecific nanobody 3B11–1C11-Fc that binds to the SARS-CoV, SARS-CoV-2, and MERS-CoV RBDs exhibited high stability and robust cross-neutralizing activity against all tested SARS-CoV, SARS-CoV-2, and MERS-CoV strains, protecting mice from infection with these three coronaviruses. Overall, the identified nanobodies, particularly the bispecific nanobody, exhibit strong neutralizing potency and protective efficacy against SARS-CoV, SARS-CoV-2, and MERS-CoV, showing the potential for further therapeutic development.

Authors

Institutions

Publication Details

Journal
ACS Nano
Published
2026-11-16
DOI
https://doi.org/10.1021/acsnano.6c10948
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Bispecific Nanobody Broadly Neutralizes and Cross-Protects against Three Highly Pathogenic Human Coronaviruses

Lanying Du, Parisa Darvishi, Li Yu, Fang Li et al.
3 links
ACS Nano
SARS-CoV-2 and COVID-19 Research
article

Bispecific Nanobody Broadly Neutralizes and Cross-Protects against Three Highly Pathogenic Human Coronaviruses

Lanying Du, Parisa Darvishi, Li Yu, Fang Li, Shengnan Qian, Xiaoqing Guan, Wandi Zhu, Abhijeet Roy, Rhea Guo, Stanley Perlman, Jianliang Xu, Chang Liu, Abhishek K. Verma, Qian Liu, Hansam Cho, Yang Yang
article en

Abstract

Abstract SARS-CoV, SARS-CoV-2, and MERS-CoV continue to infect humans or pose a threat of future outbreaks, highlighting the ongoing need for effective, broad-spectrum therapeutics that target these highly pathogenic coronaviruses. As single-domain antibodies, nanobodies have a small size, high target-binding affinity, exceptional stability, low production costs, and the ability to access otherwise hidden or cryptic epitopes. Here, we identified nanobodies targeting SARS-CoV, SARS-CoV-2, and MERS-CoV receptor-binding domains (RBDs) using phage display libraries derived from immunized nanomice and generated a bispecific nanobody to evaluate its broadly neutralizing activity and cross-protective efficacy. Nanobodies 2F11 and 4D6 targeted SARS-CoV RBD, potently neutralizing the SARS-CoV original (Tor2) strain, whereas nanobody 3B11 targeted both SARS-CoV and SARS-CoV-2 RBDs, broadly neutralizing all three SARS-CoV strains (Tor2, GD03, and SZ3) and divergent SARS-CoV-2 variants. Among MERS-CoV RBD-targeting nanobodies, 1C11 demonstrated broadly neutralizing activity against multiple MERS-CoV strains, while its Fc-fused version substantially enhanced the neutralizing potency. These nanobodies exerted neutralizing effects by blocking the interaction between the RBDs and their respective receptors. Cryo-EM structures, computational modeling, and epitope-mapping analyses revealed unique epitopes of 2F11, 3B11, and 1C11 on the SARS-CoV, SARS-CoV-2, or MERS-CoV RBD, underlying their antiviral potency. Finally, a bispecific nanobody 3B11–1C11-Fc that binds to the SARS-CoV, SARS-CoV-2, and MERS-CoV RBDs exhibited high stability and robust cross-neutralizing activity against all tested SARS-CoV, SARS-CoV-2, and MERS-CoV strains, protecting mice from infection with these three coronaviruses. Overall, the identified nanobodies, particularly the bispecific nanobody, exhibit strong neutralizing potency and protective efficacy against SARS-CoV, SARS-CoV-2, and MERS-CoV, showing the potential for further therapeutic development.

ACS Nano
The Wistar Institute (US), University of Iowa (US), University of Minnesota (US), Johns Hopkins University (US), Iowa State University (US), Georgia State University (US)
National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases
Good health and well-being
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon